Keywords: defending, brand, pharma, against, generic, threats, study
Defending brand pharma against generic threats: study
Article | 05 September 2005
When AstraZeneca said it would sell Prilosec (omeprazole) over-the-counter, the once-best-seller dropped 65% in sales from $5.5 billion in 2001 to under $2.0 billion ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
